Literature DB >> 24229725

Pharmacotherapy of cognitive deficits in schizophrenia.

Lewis A Opler1, Alice Medalia1, Mark G Opler2, Stephen M Stahl3.   

Abstract

While second-generation antipsychotics treat negative as well as positive symptoms, recovery for persons with schizophrenia remains elusive, in part because there are no FDA-approved medications that treat the cognitive deficits of schizophrenia (CDS). Recent work has identified agents that, when added to antipsychotics, improve cognition in schizophrenia. This work and hypothesized mechanisms of action will be reviewed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24229725     DOI： 10.1017/S1092852913000771

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  2 in total

Review 1.  Brain plasticity-based therapeutics.

Authors:  Michael M Merzenich; Thomas M Van Vleet; Mor Nahum
Journal:  Front Hum Neurosci       Date:  2014-06-27       Impact factor: 3.169

2.  Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: A Pilot Randomized Clinical Trial.

Authors:  Francesc Estrada; Josep Maria Crosas; Maribel Ahuir; Sara Pérez-Muñoz; Wanda Zabala; Raquel Aguayo; Juan David Barbero; Itziar Montalvo; Meritxell Tost; Laura Llauradó; Armand Guardia; Diego Palao; José Antonio Monreal; Javier Labad
Journal:  Front Psychiatry       Date:  2020-07-07       Impact factor: 4.157
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.